Morepen Laboratories Ltd Share Price Today - Morepen Laboratories Ltd Stock Price Live NSE/BSE

Morepen Laboratories Ltd

NSE: MOREPENLAB BSE: 500288

₹43.67

(-2.19%)

Wed, 04 Mar 2026, 10:55 pm

MTF 5xInvest in Morepen Laboratories Ltd with 5x Leverage Buy with MTF

Market Cap23.99B

PE Ratio24.06

Dividend0.46

Health Technology

Pharmaceuticals: Major

24.5K

Morepen Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
2283.87
Net Profit
118.02
P/B
2.27
Sector P/E
32.40
P/E
22.26
EV/EBITDA
13.91
Debt/Equity (Industry)
0.23
Interest Cover (Industry)
10.03
ROCE (Industry)
12.82
RONW (Industry)
12.23
ROE
11.78
ROCE
14.72
Debt/Equity
0.07
EPS (TTM)
1.39
Dividend Yield
0.48
Book Value
21.83
Interest Cover
19.60

Analysis

all

Pros

Morepen Laboratories is profitable, therefore cash runway is not a concern.
Morepen Laboratories is profitable, therefore cash runway is not a concern.
Debt is covered by short term assets, assets are 2.2x debt.
Morepen Laboratories's cash and other short term assets cover its long term commitments.
Interest payments on debt are well covered by earnings (EBIT is 27.2x coverage).

Cons

Unable to evaluate Morepen Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Morepen Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
Morepen Laboratories's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Operating cash flow is negative therefore debt is not well covered.
The level of debt compared to net worth has increased over the past 5 years (28.7% vs 64.2% today).

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	35.65	35.65	35.65	35.65	35.65
FII	1.62	1.62	1.72	1.94	2.22
DII	1.25	1.50	1.51	1.68	1.64
Public	61.46	61.21	61.11	60.72	60.47
Government	0.01	0.01	0.01	0.01	0.01

Technical Analysis

RSI

50.46

MACD

1.23

50 DMA

39.31

200 DMA

49.83

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	70.47	56.46	50.06	42.45	36.05	28.44	14.43
Fibonacci	56.46	51.10	47.80	42.45	37.09	33.79	28.44
Camarilla	47.52	46.24	44.95	42.45	42.39	41.10	39.82

Pivots Level: Classic

+28.02

70.47

+14.01

56.46

+7.62

50.06

42.45

Pivot Point

LTP: 40.61

-6.39

36.05

-14.01

28.44

-28.02

14.43

Moving Average

SMAEMA

Period

Value

10-EMA
41.97
20-EMA
40.88
30-EMA
40.36
50-EMA
40.44
100-EMA
42.71
200-EMA
47.46

Announcement Date	Purpose	Action	Ex Date
10 Feb 2026	board-meetings	Quarterly Results
14 Nov 2025	board-meetings	Quarterly Results
06 Aug 2025	agm
30 Jul 2025	dividend	Final Dividend - Rs. - 0.2	30 Aug 2025
29 Jul 2025	dividend	Dividend - Re 0.20 Per Share	30 Aug 2025
12 May 2025	dividend	₹0.20 Dividend /Share	30 Aug 2025
17 Jan 2025	egm
11 Sept 2024	agm
20 Aug 2024	agm	Annual General Meeting	22 Sept 2024
25 Feb 2024	egm

Morepen Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd

Cipla Ltd

Morepen Laboratories Ltd About

Morepen Laboratories is in the business of manufacturing, producing, developing, marketing and distribution of a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations, Over the Counter (OTC) products and the Home Health products.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1984

Headquarters

CEO

Sushil Suri

Employees

Contact

Website

http://www.morepen.com

investors@morepen.com

Phone

91-01795-276201-03

Location

Morepen Village, Nalagarh Road Near Baddi, Solan, Himachal Pradesh, 173205

Year	History
2005	Morepen Laboratories became the second company to join the Lipitor Club in the USA. Morepen announced 52 DMF filings for 6 products in the EU. Morepen registered 52 DMF across 10 European countries. The Company increased its holding in Doctors Morepen Ltd (DML).
2006	Mr. Manoj Joshi and Mr. B R Wadhwa were re-appointed as Directors of the Company.
2007	Morepen Lab signed a deal with Avenue Capital Group.
2011	Morepen received USFDA approval for Desloratadine.
2013	Mr. Thomas P. Joshua joined as the Company's Company Secretary and Compliance Officer.

Client Name	Order Side	QTY	Avg Price	Date
QE SECURITIES LLP	Sell	2976582	47.34	24 Feb 2026
JUNOMONETA FINSOL PRIVATE LIMITED	Sell	2954800	47.37	24 Feb 2026
NK SECURITIES RESEARCH PRIVATE LIMITED	Sell	4317619	47.41	24 Feb 2026
JUNOMONETA FINSOL PRIVATE LIMITED	Buy	2971649	47.31	24 Feb 2026
QE SECURITIES LLP	Buy	2962666	47.09	24 Feb 2026
NK SECURITIES RESEARCH PRIVATE LIMITED	Buy	4317619	47.38	24 Feb 2026
NK SECURITIES RESEARCH PRIVATE LIMITED	Buy	6404880	45.07	23 Feb 2026
QE SECURITIES LLP	Buy	3412989	45.2	23 Feb 2026
QE SECURITIES LLP	Sell	3500352	45.07	23 Feb 2026
NK SECURITIES RESEARCH PRIVATE LIMITED	Sell	6404880	45.09	23 Feb 2026

Morepen Laboratories Ltd News

Morepen Labs Secures ₹825 Crore Global CDMO Deal

Morepen Laboratories Limited has secured a multi-year CDMO mandate worth ₹825 crore from a global pharma major, marking significant expansion into high-growth contract manufacturing segment.

23 Feb 2026

co actions results

Morepen Labs Q3FY26 Net Profit Rises 3% YoY to ₹2750 Cr

Morepen Laboratories reported consolidated net profit of ₹2750.93 crores for Q3FY26, up 3% YoY. Revenue increased 7% to ₹48416 crores with strong operational performance.

10 Feb 2026

co actions results

Morepen Labs Reports Share Transfer Status Under SEBI

Morepen Laboratories submitted status report on physical share transfer re-lodgement requests under SEBI's special window. One request received during January 1-6, 2026 period was rejected.

28 Jan 2026

stocks

Morepen Labs gets HC stay on ₹117.94 cr GST notice

Himachal Pradesh High Court grants stay on GST show-cause notice alleging excess refund claims of ₹117.94 crore by Morepen Laboratories, with no immediate impact on operations.

09 Jan 2026

stocks

Morepen Lab Gets Court Stay on ₹118 Cr Tax Demand

Morepen Laboratories secures judicial relief as court grants stay on significant tax demand of ₹118 crores, providing temporary respite from regulatory proceedings.

09 Jan 2026

stocks

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800